TSTickerStarGet alerts

RNAZ 10-Q filed 2026-11-16 | Key takeaways

RNAZ filed its 10-Q; the most relevant disclosure change is added Impairment of in-process research and development: The company recorded a $102 million non-cash impairment charge to reduce the Seviprotimut-L IPR&D asset from $114.3 million to $12.3 million estimated fair value, using a multi-period excess earnings method with a 39.5% cumulative probability of regulatory app.

Share this story

Key takeaways

  • Impairment: The company recorded a $102 million non-cash impairment charge in Q3 2026 to reduce the Seviprotimut-L IPR&D asset from $114.3 million to $12.3 million estimated fair value, reflecting a sustained decline in stock price and limited funding; goodwill of $25.7 million was not impaired.

  • Going concern: Management stated there is substantial doubt about the company's ability to continue as a going concern for one year after issuance, with cash of $4.6 million sufficient to fund operations only into approximately Q1 2027.

  • Convertible notes: Approximately $4.1 million in aggregate principal remained outstanding under Yorkville convertible notes at September 30, 2026, after a $841,000 prepayment in exchange for a waiver through October 31, 2026; an amortization event occurred in November 2026 requiring monthly cash payments.

  • Preferred conversions: All Series A, B, and C Preferred Stock converted into approximately 15.9 million shares of common stock between July 20 and August 10, 2026, eliminating the preferred stock balance.

  • CFO separation: The CFO resigned in September 2026 with a $1.25 million severance agreement and 185,000 stock options granted; $833,333 of severance remained unpaid at September 30, 2026.

  • Strategic review: The board initiated a formal strategic process on October 28, 2026 to evaluate opportunities to maximize company and oncology portfolio value, including TTX-MC138.

  • Clinical trial: Phase 2a trial enrollment for TTX-MC138 in colorectal cancer MRD patients is now expected in H1 2027, delayed from prior expectations due to a collaboration with Natera and refocused recruitment efforts.

Key metrics

Net loss (Q3)Q3 2026
$107.4 millionvs $4.9 million Q3 2025
Net loss (nine months)Nine months ended September 30, 2026
$131.9 millionvs $21.2 million nine months 2025
Net loss per share (Q3)Q3 2026
$9.36vs $5.82 Q3 2025
Cash used in operating activities (nine months)Nine months ended September 30, 2026
$18.0 millionvs $11.4 million nine months 2025
Cash balanceSeptember 30, 2026
$4.6 millionvs $17.8 million at December 31, 2025
Accumulated deficitSeptember 30, 2026
$229.8 millionvs $97.9 million at December 31, 2025
IPR&D impairmentThree months ended September 30, 2026
$102.0 millionnew charge
Seviprotimut-L IPR&D carrying valueSeptember 30, 2026
$12.3 millionvs $114.3 million at acquisition

Disclosure changes

  • Impairment of in-process research and development

    The company recorded a $102 million non-cash impairment charge to reduce the Seviprotimut-L IPR&D asset from $114.3 million to $12.3 million estimated fair value, using a multi-period excess earnings method with a 39.5% cumulative probability of regulatory approval, 19.0% discount rate, and expected commercialization in 2043.

    This is a significant write-down of the largest asset acquired in the Polynoma transaction, reflecting the company's limited funding and market capitalization decline.
  • Going concern

    Management stated there is substantial doubt about the company's ability to continue as a going concern for one year after issuance without additional capital, with cash of $4.6 million sufficient only into approximately Q1 2027.

    The runway has shortened from year-end 2026 to approximately Q1 2027, and the company faces convertible note amortization payment obligations.
  • Convertible notes and SEPA

    Yorkville convertible notes with $6.0 million aggregate principal had $4.1 million outstanding at September 30, 2026; a $841,000 prepayment was made in September 2026 for a waiver through October 31, 2026; an amortization event occurred in November 2026 requiring monthly cash payments of 18% of outstanding principal plus 10% premium and accrued interest.

    The company faces potential monthly cash payment obligations under the convertible notes if stock price remains below the $1.72 floor price, creating liquidity pressure.
  • Subsequent events - strategic review

    On October 28, 2026, the board announced a formal strategic process to evaluate opportunities to maximize company and oncology portfolio value, including TTX-MC138; there can be no assurance the process will result in any transaction.

    The board is actively exploring strategic alternatives, which could include a sale, partnership, or other transaction affecting stockholder value.
  • Subsequent events - convertible notes amortization

    After the waiver period ended October 31, 2026, the company's daily VWAP remained below the $1.72 floor price and an amortization event occurred in November 2026; the company is required to make monthly cash payments unless the event is waived.

    Monthly cash payments could significantly impact liquidity; the company is in discussions with Yorkville for relief.
  • Subsequent events - Wheeler settlement

    On November 6, 2026, the company settled the Wheeler Action with no cash payment; Polynoma relinquished laboratory equipment and the company waived amounts previously invoiced to Wheeler, recognizing a $292,000 loss.

    The litigation is resolved without cash outlay but resulted in a non-cash loss and loss of equipment assets.

Primary source

TickerStar generated this brief from an official company, investor-relations, earnings-call, or regulatory source. Review the primary material before making an investment decision.

Open SEC filing

Follow RNAZ in real time

Get material earnings, filing, IR, and earnings-call alerts by email.

Create a free alert